Publications by authors named "Bassem Talaat"

4 Publications

  • Page 1 of 1

Determining the Optimal Time Interval Between Vaginal Dinoprostone Administration and Diagnostic Office Hysteroscopy in Nulliparous Women: A Randomized Double-Blind Trial.

J Minim Invasive Gynecol 2021 Jul 1. Epub 2021 Jul 1.

Department of Obstetrics &Gynecology, Faculty of Medicine, Cairo University, Cairo, Egypt.

Study Objective: To determine optimal timing of vaginal dinoprostone administration before office hysteroscopy (OH) in nullipara.

Design: Randomized double-blinded trial SETTING: Tertiary referral hospital PATIENTS: 180 nulliparous women undergoing diagnostic OH INTERVENTIONS: We randomly allocated women to long-interval or short-interval dinoprostone groups where 3 mg dinoprostone was administered vaginally 12 hours before OH in long-interval group or 3 hours before OH in short-interval group.

Measurements And Main Results: The primary outcome was pain during OH measured by a 100-mm visual analog scale(0=no pain; 100=worst pain imaginable). Secondary outcomes were ease of hysteroscope passage, women satisfaction score, drug side effects. Long-interval dinoprostone had lower pain scores during OH(P <0.001). Contrarily, pain scores 30 minutes postprocedure were similar in both groups(P=0.1). Women were more satisfied, and clinicians found hysteroscope passage through the cervical canal easier and shorter in long-interval dinoprostone group than short-interval group(P<.001&P=0.003 &P<.001, respectively). Side effects were comparable in both study groups.

Conclusion: Vaginal dinoprostone 12 hours before OH was more effective than vaginal dinoprostone administrated 3 hours before OH in reducing pain during OH in nulliparous patients with easier hysteroscope insertion, shorter procedure duration, and better women satisfaction score.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmig.2021.06.021DOI Listing
July 2021

Perioperative nonhormonal pharmacological interventions for bleeding reduction during open and minimally invasive myomectomy: a systematic review and network meta-analysis.

Fertil Steril 2020 01 18;113(1):224-233.e6. Epub 2019 Nov 18.

Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Cairo, Egypt.

Objective: To synthesize evidence on the most effective pharmacological interventions for bleeding reduction during open and minimally invasive myomectomy.

Design: Systematic review and network meta-analysis of randomized controlled trials (RCTs).

Setting: Not applicable.

Patients: Trials assessing efficacy of pharmacological interventions during different types of myomectomy.

Interventions: Misoprostol, oxytocin, vasopressin, tranexamic acid (TXA), epinephrine, or ascorbic acid.

Main Outcome Measures: Intraoperative blood loss and need for blood transfusion.

Results: The present review included 26 randomized control trials (RCTs) (N = 1627). For minimally invasive procedures (9 RCTs; 474 patients), network meta-analysis showed that oxytocin (mean difference [MD] -175.5 mL, 95% confidence interval [CI] -30.1.07, -49.93), ornipressin (MD -149.6 mL, 95% CI - 178.22, -120.98), misoprostol, bupivacaine plus epinephrine, and vasopressin were effective in reducing myomectomy blood loss, but the evidence is of low quality. Ranking score of treatments included in subgroup analysis of minimally invasive myomectomy showed that oxytocin ranked first in reducing blood loss, followed by ornipressin. For open myomectomy (17 RCTs; 1,153 patients), network meta-analysis showed that vasopressin plus misoprostol (MD -652.97 mL, 95% CI - 1113.69, -174.26), oxytocin, TXA, and misoprostol were effective; however, the evidence is of low quality. Vasopressin plus misoprostol ranked first in reducing blood loss during open myomectomy (P = .97).

Conclusion: There is low-quality evidence to support uterotonics, especially oxytocin, and peripheral vasoconstrictors as effective options in reducing blood loss and need for blood transfusion during minimally invasive myomectomy. Oxytocin is the most effective intervention in minimally invasive myomectomy. For open myomectomy, a combination of uterotonics and peripheral vasoconstrictors is needed to effectively reduce blood loss.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.fertnstert.2019.09.016DOI Listing
January 2020

Vaginal Dinoprostone in Reducing Pain Perception During Diagnostic Office Hysteroscopy in Postmenopausal Women: A Randomized, Double-Blind, Placebo-Controlled Trial.

J Minim Invasive Gynecol 2020 May - Jun;27(4):847-853. Epub 2019 Aug 1.

Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Cairo, Egypt (Drs. Samy, Rashwan, Metwally, Hammad, Ibrahim, Elzahaby, Zaki, and Sharkawy).

Study Objective: To evaluate the efficacy of vaginal dinoprostone in reducing pain perception during diagnostic office hysteroscopy (OH) in postmenopausal women.

Design: Randomized, double-blind controlled trial.

Setting: Tertiary university hospital.

Participants: Postmenopausal patients scheduled for OH.

Interventions: Eligible participants were randomized in a 1:1 ratio to the dinoprostone and placebo groups. The severity of pain was assessed with a visual analog scale (VAS) ranging from 0, no pain to 10, worst pain during OH and 30 minutes after OH.

Measurements And Main Results: The difference in the intensity of pain using the VAS score during the procedure. One hundred women (50 in each arm) were included in the study. The mean VAS score during OH was significantly lower in the dinoprostone group compared with the placebo group (3.9 ± 0.8 vs 5.6 ± 0.7; p <.001). The passage of the hysteroscope through the cervical canal was easier in the dinoprostone group (62.4 ± 9.5 vs 42.8 ± 10.8; p <.001). The 2 groups were comparable in terms of the duration of the procedure (p = .91) and the rate of adverse effects.

Conclusion: Vaginal dinoprostone is effective in relieving pain during diagnostic OH in postmenopausal women with few adverse effects.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmig.2019.07.026DOI Listing
August 2019

The Effect of Zumba Exercise on Reducing Menstrual Pain in Young Women with Primary Dysmenorrhea: A Randomized Controlled Trial.

J Pediatr Adolesc Gynecol 2019 Oct 11;32(5):541-545. Epub 2019 Jun 11.

Faculty of Medicine, Al-Azhar University, Cairo, Egypt.

Study Objective: To study the effectiveness of performing Zumba exercise on the severity and duration of pain in patients with primary dysmenorrhea.

Design: Randomized controlled trial.

Setting: Cairo University gynecology Hospital and Bahgat gym and fitness center.

Participants: Ninety-eight women diagnosed with primary dysmenorrhea.

Interventions: Study participants were divided randomly into 2 equal groups: group I included women who engaged in Zumba exercise for 60 minutes twice weekly for 8 weeks, and group II was a control group with no intervention.

Main Outcome Measures: The primary outcome was the menstrual pain intensity measured using the visual analogue scale scores at 4 and 8 weeks after starting Zumba exercise. The secondary outcome was the difference in the duration of pain in both groups.

Results: Both groups were homogeneous regarding the baseline demographic characteristics. The severity of primary dysmenorrhea at the beginning of the study was not significantly different between the 2 groups. Menstrual pain intensity was significantly decreased in the Zumba group after 4 and 8 weeks of Zumba compared with the control group (mean difference, -2.94 [95% confidence interval, -3.39 to -2.48] and -3.79 [95% confidence interval, -4.16 to -3.43], respectively; P = .001). Also, the duration of pain was shorter in the Zumba group compared with the control group at 8 weeks (4.92 ± 1.90 vs 9.10 ± 2.92 hours, respectively; P = .001).

Conclusion: The Zumba intervention can reduce the severity and duration of menstrual pain thus suggesting that regularly performing Zumba might be a possible complementary treatment for primary dysmenorrhea.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpag.2019.06.001DOI Listing
October 2019
-->